Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 3/20 | 0.34 |
| ▸ | PARP1 | P09874 | 4/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752317 | 0.82 | HTR2C (0.39) | HTR2CKDM4EALDH1A1MAPTHTT | |
| SCHEMBL5246381 | 0.80 | PARP1 (0.34) | PARP1 | |
| SCHEMBL3744443 | 0.79 | THRB (0.35) | PARP1 | |
| SCHEMBL5244562 | 0.78 | PARP1 (0.33) | PARP1 | |
| SCHEMBL3178005 | 0.76 | NPC1 (0.34) | PARP14PARP1KDM4EALDH1A1MAPT | |
| SCHEMBL4638534 | 0.76 | — | — | |
| SCHEMBL3753729 | 0.76 | LMNA (0.36) | PARP1 | |
| SCHEMBL5245345 | 0.75 | PARP1 (0.32) | PARP1 | |
| SCHEMBL3759067 | 0.75 | LMNA (0.38) | PARP1 | |
| SCHEMBL3749097 | 0.74 | PARP1 (0.38) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | PARP14 4538/4885PARP1 4719/4885HTR2C 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.